Implantation of the Cochlear™ Nucleus® Hybrid S Round Window (S-RW) in Adults
Launched by COCHLEAR · Dec 21, 2015
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
The Food and Drug Administration recently approved the Cochlear Nucleus Hybrid L24 Implant System (P130016) for individuals aged 18 years and older who present with bilateral residual low frequency hearing sensitivity and severe to profound high frequency sensorineural hearing loss with limited benefit from appropriately fitted bilateral amplification. Additionally, the Nucleus Hybrid S12 Implant has been under evaluation since 2007 (IDE G#070016). The Nucleus Hybrid S-RW is a modification of the current Hybrid S12 implant. The Hybrid S-RW is designed to support implantation via a round win...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Eighteen years of age or older at the time of implantation
- • 2. Sensorineural hearing loss with the following requirements: a pure tone threshold less (better) than or equal to 60 dB HL at 500 Hz,less than (better) or equal to 80 dB HL at 1500 Hz, and high frequency severe to profound (a threshold average of 2000, 3000, \& 4000 Hz) of \> 60dB HL.
- • 3. Minimum of 30 days experience with appropriately fit bilateral amplification, fit as described in the Fitting and Use of Hearing Aids section below
- • 4. Aided monosyllabic word score (e.g., CNC Word Test) (mean of two lists) between 20% and 60%, inclusive (i.e., 20% score 60%), in the ear to be implanted
- • 5. Aided monosyllabic word score (e.g., CNC Word Test) (mean of two lists) in the contralateral ear equal to, or better than, the ear to be implanted but not more than 80%
- • 6. Willingness to use bimodal stimulation (i.e., a cochlear implant on one ear and a hearing aid on the contralateral ear) through 12-months post-activation
- Exclusion Criteria:
- • 1. Individuals aged greater than 75 years
- • 2. Duration of severe to profound hearing loss (above 2kHz) greater than 20 years
- • 3. Medical or psychological conditions that contraindicate undergoing surgery as determined by the Investigator
- • 4. Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array
- • 5. Conductive overlay of 15 dB or greater at two or more frequencies, in the range 500 to 1000 Hz
- • 6. Deafness due to lesions of the acoustic nerve or central auditory pathway
- • 7. Active middle-ear infection or tympanic membrane perforation in the presence of active middle ear disease
- • 8. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator
- • 9. Unwillingness or inability of the candidate to comply with all investigational requirements as determined by the Investigator
- • 10. Additional handicaps that would prevent or restrict participation in the audiological evaluations as determined by the Investigator.
About Cochlear
Cochlear Limited is a global leader in implantable hearing solutions, dedicated to transforming the lives of individuals with hearing loss through innovative technology and comprehensive clinical research. With a strong commitment to advancing auditory rehabilitation, Cochlear conducts rigorous clinical trials aimed at evaluating the safety and efficacy of its products, including cochlear implants and bone conduction devices. The company collaborates with healthcare professionals and research institutions worldwide to ensure that its solutions meet the highest standards of quality and performance, ultimately enhancing patient outcomes and promoting accessibility to hearing health care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Des Moines, Iowa, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials